{
    "clinical_study": {
        "@rank": "82426", 
        "arm_group": [
            {
                "arm_group_label": "Arm 1: semaglutide + moxifloxacin placebo", 
                "arm_group_type": "Experimental", 
                "description": "Subjects will receive a single dose of moxifloxacin placebo both before the start of semaglutide treatment and at the end of the semaglutide treatment."
            }, 
            {
                "arm_group_label": "Arm 2A:", 
                "arm_group_type": "Active Comparator", 
                "description": "Semaglutide placebo + moxifloxacin/moxifloxacin placebo:\nSubjects will receive moxifloxacin before the start of semaglutide placebo treatment and moxifloxacin placebo at the end of the semaglutide placebo treatment."
            }, 
            {
                "arm_group_label": "Arm 2B:", 
                "arm_group_type": "Experimental", 
                "description": "Semaglutide placebo + moxifloxacin placebo/moxifloxacin:\nSubjects will receive moxifloxacin placebo before the start of semaglutide placebo treatment and moxifloxacin at the end of the semaglutide placebo treatment."
            }
        ], 
        "brief_summary": {
            "textblock": "This trial is conducted in Europe. The aim of the trial is to evaluate the effect of\n      semaglutide on cardiac repolarisation in healthy subjects."
        }, 
        "brief_title": "A Thorough QTc Evaluation of the Effect of Semaglutide on Cardiac Repolarisation in Healthy Subjects", 
        "completion_date": {
            "#text": "March 2015", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Diabetes", 
            "Healthy"
        ], 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  BMI (Body Mass Index): 20-30 kg/m^2\n\n          -  Body weight: 60-110 kg\n\n          -  Normal ECG (electrocardiogram)\n\n        Exclusion Criteria:\n\n          -  Female who is pregnant, breast-feeding or intends to become pregnant or is of\n             child-bearing potential and not using an adequate contraceptive method. Women of\n             child-bearing potential must use an effective method of birth control for the\n             duration of the trial and for 5 weeks following the last dose of semaglutide. Only\n             highly effective methods of birth control are accepted (i.e. one that results in less\n             than 1% per year failure rate when used consistently and correctly such as implants,\n             injectables, combined oral contraceptives, some intrauterine devices), or sexual\n             abstinence or vasectomised partner\n\n          -  Any clinically significant disease history, in the opinion of the investigator, or\n             systemic or organ\n\n          -  History of seizures, epilepsy, syncope, cardiac arrest, cardiac arrhythmia or\n             Torsades de Pointes, A-V (Atrioventricular) block or structural heart disease\n\n          -  Family history of long QT (Interval in the ECG: from the start of the QRS complex to\n             the end) syndrome (either objectively diagnosed or suggested by sudden death due to\n             cardiac causes before the age of 50 of a 1st degree relative)\n\n          -  Family history of sudden cardiac death before the age of 50 of a 1st degree relative\n\n          -  Use of prescription or non-prescription systemic or topical medicinal products\n             (except routine vitamins, acetylsalicylic acid, paracetamol and contraceptives)\n             within 3 weeks (or within 5 halflives of the medicinal product, whichever is longest)\n             prior to the first dosing of semaglutide\n\n          -  Smoking, drug or alcohol abuse"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "55 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "168", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 13, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02064348", 
            "org_study_id": "NN9535-3652", 
            "secondary_id": [
                "2012-005073-31", 
                "U1111-1136-6455"
            ]
        }, 
        "intervention": [
            {
                "arm_group_label": "Arm 1: semaglutide + moxifloxacin placebo", 
                "description": "Solution for subcutaneous (s.c., under the skin) injection. Dose escalation to 1.5 mg.", 
                "intervention_name": "semaglutide", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Arm 1: semaglutide + moxifloxacin placebo", 
                    "Arm 2A:", 
                    "Arm 2B:"
                ], 
                "description": "Solution for s.c. injection or tablets for oral administration", 
                "intervention_name": "placebo", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Arm 2A:", 
                    "Arm 2B:"
                ], 
                "description": "Tablets for oral administration", 
                "intervention_name": "moxifloxacin", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Moxifloxacin", 
                "Norgestimate, ethinyl estradiol drug combination"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "May 27, 2014", 
        "link": {
            "description": "Clinical Trials at Novo Nordisk", 
            "url": "http://novonordisk-trials.com"
        }, 
        "location": {
            "facility": {
                "address": {
                    "city": "Berlin", 
                    "country": "Germany", 
                    "zip": "14050"
                }
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Germany"
        }, 
        "number_of_arms": "3", 
        "official_title": "A Thorough QTc Evaluation of the Effect of Semaglutide on Cardiac Repolarisation in Healthy Subjects: A Randomised, Double-Blind,Placebo-Controlled, Three-Arm Parallel Trial With a Nested Cross-Over Design for Positive Control With Moxifloxacin Administration", 
        "overall_contact": {
            "email": "clinicaltrials@novonordisk.com", 
            "last_name": "Novo Nordisk"
        }, 
        "overall_official": {
            "affiliation": "Novo Nordisk A/S", 
            "last_name": "Global Clinical Registry (GCR, 1452)", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Germany: Federal Institute for Drugs and Medical Devices", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "March 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "QTcI, (Individual heart rate corrected QT (Interval in the ECG: from the start of the QRS complex to the end) interval) based on ECG recordings obtained at 11 time points", 
            "safety_issue": "No", 
            "time_frame": "0-48 hours after the fourth dose of semaglutide/semaglutide placebo at the 1.5 mg dose level"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02064348"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "QTcI, based on ECG (electrocardiogram) recordings obtained at 2 out of 8 time points", 
            "safety_issue": "No", 
            "time_frame": "0-24 hours after a single dose of moxifloxacin/moxifloxacin placebo"
        }, 
        "source": "Novo Nordisk A/S", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Novo Nordisk A/S", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "February 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}